Abbott Laboratories earnings calendar, shares in focus on the NYSE

By Mark Bergmann, Earnings & Calendar desk. Reviewed prior to publication on 2026-06-30, 09:48.

Abbott Laboratories (US0028241000) starts this week with a clear earnings calendar as the next quarterly update approaches for the NYSE-listed healthcare group. The stock remains a core component of many US healthcare portfolios, with investors watching upcoming results for signals on margins and growth.

Earnings dates on the calendar

Abbott customarily reports its second-quarter figures in mid-July, and investors expect a detailed update on revenue trends across diagnostics, medical devices, nutrition, and established pharmaceuticals. The reporting rhythm has been consistent over recent years, with quarterly earnings calls providing guidance ranges and commentary on demand conditions in key markets such as the United States and Europe.

In prior quarters, the company has typically scheduled its earnings call before the US market open, allowing NYSE trading to digest the numbers and guidance throughout the regular session. This timing matters for retail investors, because pre-market reactions can set the tone for the trading day in Abbott shares, while institutional investors parse details on segment margins and capital allocation plans.

Analyst consensus and expectations

On the analyst side, large US and international houses such as Goldman Sachs, JPMorgan, and Morgan Stanley usually maintain active coverage on Abbott, providing earnings-per-share estimates, revenue forecasts, and commentary on medium-term growth drivers. Consensus estimates for the upcoming quarter tend to center on modest mid-single-digit revenue growth and stable to slightly expanding margins, reflecting Abbott's diversified portfolio and ongoing cost discipline.

Rating distributions at major data aggregators commonly show a majority of Buy and Overweight recommendations, with a smaller group of Hold ratings and few underweight stances. Price targets from these houses often reference Abbott's position within the US healthcare sector, comparing valuation multiples such as forward price-to-earnings ratios to peers like Johnson & Johnson, Medtronic, and Boston Scientific. This peer framing helps investors understand whether Abbott trades at a premium or discount to its sector, and whether consensus expects the shares to benefit from future execution on growth and profitability.

How Abbott makes its money

Abbott generates revenue across four major segments: diagnostics, medical devices, nutrition, and established pharmaceuticals. A flagship product line is the FreeStyle Libre continuous glucose monitoring system for diabetics, which provides sensor-based glucose readings and recurring revenue through sensors and readers in many international markets.

Where the shares trade today

Abbott Laboratories shares (US0028241000) trade on the NYSE, with the latest verifiable price data showing the stock quoted in US dollars during the regular US trading session. The company is part of major US equity indices, and the shares remain widely followed by both institutional and retail investors.

This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. All data are based on the latest available information and may change over time. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.